share_log

健康元(600380.SH):控股子公司丽珠集团司美格鲁肽的糖尿病适应症已完成III期临床入组

Health Source (600380.SH): The diabetes indications of the holding subsidiary Livou Group Simeglutide have completed phase III clinical enrollment

Gelonghui Finance ·  Dec 27, 2023 02:58

Gelonghui, December 27丨Health Yuan (600380.SH) said on an interactive platform that the company's holding subsidiary Lizhu Group Simeglutide's diabetes indications have completed phase III clinical enrollment, and research and development is progressing smoothly. Since the weight loss indications of the original research drug of this variety have not yet been approved domestically, the country needs to be approved for this indication before clinical trials can be carried out. The company will actively follow up on related work in the future. If there is any relevant progress, the company will fulfill its information disclosure obligations in accordance with regulations.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment